27 results
DEFM14A
SQZB
SQZ Biotechnologies Co
23 Jan 24
Proxy related to merger
4:31pm
of immune cells to discover new targets in cancer immunotherapy. The 2017 Roche Agreement includes several licenses granted by Roche to us and by us … our Cell Squeeze technology to enable gene editing of immune cells to discover new targets in cancer immunotherapy. The 2017 Roche Agreement includes
PREM14A
SQZB
SQZ Biotechnologies Co
12 Jan 24
Preliminary proxy related to merger
8:57am
to enable gene editing of immune cells to discover new targets in cancer immunotherapy. The 2017 Roche Agreement includes several licenses granted … , to allow Roche to use our Cell Squeeze technology to enable gene editing of immune cells to discover new targets in cancer immunotherapy. The 2017
8-K
EX-99.1
SQZB
SQZ Biotechnologies Co
6 Dec 22
Designation Represents Potential to Bring Important New Therapy to Patients Earlier
4:23pm
or metastatic solid tumors. The clinical candidate, which targets E6 and E7 oncoproteins, is being studied as a monotherapy and in combination … or metastatic solid tumors. Patients must be positive for the human leukocyte antigen serotype HLA-A*02. The investigational candidate, which targets
8-K
EX-99.1
wgiskzra
31 May 22
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease
4:52pm
8-K
EX-99.1
jbp9r n9q
24 Jan 22
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
7:01am
8-K
EX-99.1
35bin
9 Dec 21
Other Events
7:30am
8-K
EX-99.1
t810 zdskh3
2 Dec 21
Other Events
6:28am
8-K
EX-99.1
p0944x 5zhl
26 Oct 21
SQZ Biotechnologies Announces Independent DSMB Recommendation to Advance Lead Cell Therapy Candidate into Combination
6:54am
8-K
EX-99.1
6qno5mbro1w vw
4 Jun 21
Regulation FD Disclosure
8:09am
10-K
hiv4all xpfnvmy
18 Mar 21
Annual report
6:31am
424B4
26ypucil4jpsokbicqe
12 Feb 21
Prospectus supplement with pricing info
5:10pm
DRS
aqdrb
1 Feb 21
Draft registration statement
12:00am